Overview

Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)

Status:
RECRUITING
Trial end date:
2030-03-27
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the safety and tolerability of subcutaneous (SC) tarlatamab.
Phase:
PHASE1
Details
Lead Sponsor:
Amgen
Treatments:
AMG 757